Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Speetjens FM, Welters MJP, Slingerland M, van Poelgeest MIE, de Vos van Steenwijk PJ, Roozen I, Boekestijn S, Loof NM, Zom GG, Valentijn ARPM, Krebber WJ, Meeuwenoord NJ, Janssen CAH, Melief CJM, van der Marel GA, Filippov DV, van der Burg SH, Gelderblom H, Ossendorp F. Speetjens FM, et al. Among authors: gelderblom h. J Immunother Cancer. 2022 Oct;10(10):e005016. doi: 10.1136/jitc-2022-005016. J Immunother Cancer. 2022. PMID: 36261215 Free PMC article. Clinical Trial.
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
de Jonge MJ, Slingerland M, Loos WJ, Wiemer EA, Burger H, Mathijssen RH, Kroep JR, den Hollander MA, van der Biessen D, Lam MH, Verweij J, Gelderblom H. de Jonge MJ, et al. Among authors: gelderblom h. Eur J Cancer. 2010 Nov;46(16):3016-21. doi: 10.1016/j.ejca.2010.07.015. Epub 2010 Aug 26. Eur J Cancer. 2010. PMID: 20801016 Clinical Trial.
The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan.
Slingerland M, Gelderblom H. Slingerland M, et al. Among authors: gelderblom h. Invest New Drugs. 2012 Jun;30(3):1208-10. doi: 10.1007/s10637-011-9679-4. Epub 2011 May 6. Invest New Drugs. 2012. PMID: 21547368 Free PMC article. Clinical Trial.
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, Morreau H, van der Burg SH, Guchelaar HJ, van Hall T. Pander J, et al. Among authors: gelderblom h. Clin Cancer Res. 2011 Sep 1;17(17):5668-73. doi: 10.1158/1078-0432.CCR-11-0239. Epub 2011 Jul 25. Clin Cancer Res. 2011. PMID: 21788356
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, Kapiteijn E, Gelderblom H, Nijman HW, Valentijn AR, Oostendorp J, Fathers LM, Drijfhout JW, van de Velde CJ, Kuppen PJ, van der Burg SH, Melief CJ. Zeestraten EC, et al. Among authors: gelderblom h. Int J Cancer. 2013 Apr 1;132(7):1581-91. doi: 10.1002/ijc.27819. Epub 2012 Nov 21. Int J Cancer. 2013. PMID: 22948952 Free article. Clinical Trial.
858 results